Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. 2002

Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
Department of Virology/NN10, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. quinonm@ccf.org

Recent studies have shown that the accumulation of multiple mutations associated with nucleoside reverse transcriptase inhibitor (NRTI) resistance may be grouped as multi-NRTI resistance (MNR) complexes. In this study, we have examined the viral fitness of recombinant viruses carrying the reverse transcriptase (RT) of a human immunodeficiency virus type 1 (HIV-1) primary isolate harboring mutations comprising the MNR 69 insertion complex. Different RT mutants were prepared in the sequence context of either the wild-type RT sequence of the HIV-1(BH10) isolate or the sequence found in a clinical HIV-1 isolate with the MNR 69 insertion mutation. As expected, in the presence of zidovudine, recombinant viruses harboring the MNR RT from the patient were more fit than wild-type viruses. However, in the absence of drug, the virus with the RT from the original clinical isolate (SS) was more fit than (i) the wild-type virus with an engineered serine insertion between residues 69 and 70 (T69SSS) and (ii) the recombinant virus with the MNR RT where the insertion was removed (2S0S). These results suggest that RT insertions, in the right sequence context (i.e., additional mutations contained in the MNR 69 insertion complex), enhance NRTI resistance and may improve viral fitness. Thus, comparing complex mutation patterns with viral fitness may help to elucidate the role of uncharacterized drug resistance mutations in antiretroviral treatment failure.

UI MeSH Term Description Entries
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016254 Mutagenesis, Insertional Mutagenesis where the mutation is caused by the introduction of foreign DNA sequences into a gene or extragenic sequence. This may occur spontaneously in vivo or be experimentally induced in vivo or in vitro. Proviral DNA insertions into or adjacent to a cellular proto-oncogene can interrupt GENETIC TRANSLATION of the coding sequences or interfere with recognition of regulatory elements and cause unregulated expression of the proto-oncogene resulting in tumor formation. Gene Insertion,Insertion Mutation,Insertional Activation,Insertional Mutagenesis,Linker-Insertion Mutagenesis,Mutagenesis, Cassette,Sequence Insertion,Viral Insertional Mutagenesis,Activation, Insertional,Activations, Insertional,Cassette Mutagenesis,Gene Insertions,Insertion Mutations,Insertion, Gene,Insertion, Sequence,Insertional Activations,Insertional Mutagenesis, Viral,Insertions, Gene,Insertions, Sequence,Linker Insertion Mutagenesis,Mutagenesis, Linker-Insertion,Mutagenesis, Viral Insertional,Mutation, Insertion,Mutations, Insertion,Sequence Insertions
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
January 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
July 2010, Virology,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
April 2009, Journal of virology,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
October 2003, The Journal of infectious diseases,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
March 1995, The Journal of infectious diseases,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
October 2008, AIDS research and human retroviruses,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
January 2007, Antimicrobial agents and chemotherapy,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
August 2006, Antimicrobial agents and chemotherapy,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
January 2004, Current topics in medicinal chemistry,
Miguel E Quiñones-Mateu, and Mahlet Tadele, and Mariona Parera, and Antonio Mas, and Jan Weber, and Héctor R Rangel, and Bikram Chakraborty, and Bonaventura Clotet, and Esteban Domingo, and Luis Menéndez-Arias, and Miguel A Martínez
January 2006, Current pharmaceutical design,
Copied contents to your clipboard!